GlassScriptPhysician profile
Joseph Benny Haddad
NPI 1518978428
$3,366.22
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $460 · 2021: $857 · 2022: $876 · 2023: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.73 | 2019-2023 | |
| Pfizer INC. | $359.10 | 2019-2023 | |
| Novo Nordisk INC | $299.17 | 2019-2023 | Wegovy |
| Therapeuticsmd, INC. | $240.41 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.19 | 2019-2023 | Trulance, Xifaxan |
| Myovant Sciences INC. | $157.87 | 2021-2022 | |
| Coopersurgical, INC. | $157.70 | 2019 | |
| Mayne Pharma Commercial LLC | $130.92 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $120.15 | 2023 | Myfembree |
| Astellas Pharma US INC | $119.35 | 2019-2022 | |
| Lupin INC. | $93.36 | 2019-2021 | |
| Organon LLC | $81.22 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $70.54 | 2019 | |
| Scynexis, INC. | $49.32 | 2022 | |
| Agile Therapeutics, INC. | $46.81 | 2021-2023 | Twirla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $44.87 | 2020-2022 | |
| Ascend Therapeutics US, LLC | $38.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.36 | 2019-2020 | |
| Evofem Biosciences, INC. | $36.90 | 2021 | |
| Eisai INC. | $35.91 | 2019 | |
| Vertical Pharmaceuticals, LLC | $30.83 | 2019 | |
| Currax Pharmaceuticals LLC | $30.14 | 2019-2023 | Contrave |
| Nalpropion Pharmaceuticals LLC | $30.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.25 | 2022 | |
| Hologic Sales and Service, LLC | $22.91 | 2020 | |
| Renovia INC | $16.55 | 2021 | |
| Duchesnay USA Incorporated | $15.78 | 2019 | |
| Minerva Surgical, INC | $14.76 | 2023 | |
| Allergan, INC. | $13.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.00 | 2019 | |
| Acella Pharmaceuticals, LLC | $11.75 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.